- Investor Relations
Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.
To become harmful, tumors must develop blood vessels. Conventional methods for identifying cancer cells that promote tumor blood vessel formation are complicated, labor intensive and commonly require expensive reagents. This has led researchers at Harvard Medical School and Boston Children’s Hospital to develop a simple and non-invasive method to distinguish between tumor cells that do and do not promote the formation of blood vessels. The development work has resulted in the video protocol “A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells”, which was recently published in the video journal JoVE.
In December 2015, PHI and Boston Children’s Hospital agreed to evaluate PHI’s HoloMonitor technology for applications in cell-based cancer research. For more information regarding this research and Boston Children’s Hospital, see the CEO commentary “No Blood, No Tumor”.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.